If you take the key point, increasing valuations based on improved valuation of life insurance policies - based on stats below on US life expectancy improvement during the last five years from 77 to 79.6 years, they would be hard pressed to justify an uplift in value. https://www.worldometers.info/demographics/us-demographics/
This is not to say the Abacus team have been targeting those closer to death. This would definitely improve valuations above competitors, however given their leadership position in the market it would be hard to believe they could do this at volume.
The other potential factor of re-rating up is the potential of Trump policies killing people earlier due to cutting back of Medicaid.
Morbid topic, but this is the secondary life insurance market in the US.
PAC Price at posting:
$10.54 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)